Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated

Know Labs, Inc.

Americans with diabetes have been relying on insulin injections to manage their illness for decades. Those injections can be painful, expensive and inconvenient. The daily invasive testing regimen adds to that pain and inconvenience. But new developments from companies such as Novo Nordisk A/S (NYSE: NVO), Rockley Photonics Holdings Ltd (NYSE: RKLY), Movano Inc (NASDAQ: MOVE) and Know Labs Inc. (OTCQB: KNWN) are reportedly on the verge of changing the game for those dealing with diabetes. The U.S. Food and Drug Administration (FDA) recently approved Rybelsus, also known as oral semaglutide, which controls blood sugar in Type 2 diabetes patients. Novo, which developed Rybelsus, has not revealed what the pill will cost. Still, the company claims it is committed to working with health insurance providers and pharmacy benefit managers to increase patient access. Novo is not yet done and is awaiting more guidance from the FDA on a second Rybelsus indication — reducing the risk of cardiovascular issues in Type 2 diabetes patients. The price of insulin products has been soaring with Novo, Eli Lilly and Co. (NYSE: LLY) and Sanofi SA (NASDAQ: SNY) controlling most of the world’s nearly $30 billion insulin market. Ninety percent of commercially insured patients with Type 2 diabetes are prescribed newer versions of insulin that are more effective and more accessible to administer than the costlier versions. Insulin prices have risen more than 15% across the board in the last 10 years. Newer versions of insulin retail for between $175 and $300 per vial, but several moves have been made in the commercial sector to address affordability. This includes insurance company Cigna Corp. ’s (NYSE: CI) pharmacy benefit Express Scripts division announcing a new program that caps out-of-pocket costs for patients with diabetes at $25 per month. Beyond the cost and availability of insulin is the issue of invasive or minimally invasive blood glucose diagnostics, which is also seemingly on the verge of change due to companies like Seattle-based Know Labs. The company says its Bio-RFID™ technology uses radio-frequency spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into various wearable, mobile or bench-top form factors. That would make it possible to effectively identify and monitor biomarkers that could only previously be performed by invasive, expensive and time-consuming lab-based tests. Know Labs recently announced it was granted two new foundational patents for its proprietary Bio-RFID™ technology. The patents allow the company to protect its ability to create and use any database built with data captured through its noninvasive sensors. The Company believes this widens their technological gap to others pursuing non-invasive diagnostics, such as Movano and Rockley. Know Labs believes it could become the first company to bring an FDA-cleared noninvasive glucose monitoring device to market. It is conducting a 200-person internal clinical trial of Bio-RFID, which will help refine its algorithm and confirm its Bio-RFID accuracy. This could be a significant milestone towards regulatory clearance and ultimately product commercialization, potentially changing the lives of millions worldwide. For more information on Know Labs, Inc., visit www.knowlabs.co. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Know Labs Know Labs info@visualant.net Company Website http://www.knowlabs.co

August 18, 2022 07:01 PM Eastern Daylight Time

GROUNDWORK BIOAG RAISES $18 MILLION TO ACCELERATE DECARBONIZATION OF MAINSTREAM AGRICULTURE

Groundwork BioAg

Groundwork BioAg, a leading producer of mycorrhizal inoculants with broad benefits for mainstream agriculture, has completed an $18 million Series B raise. The round was led by Climate Innovation Capital (ClimateIC) with participation from HSBC Global Asset Management (HSBC), BASF Venture Capital, and Edaphon (a climate-focused fund), as well as individual investor John Abele, Co-Founder and former CEO of Boston Scientific. All previous investors, including MoreVC, Middleland Capital, and Ibex Investors also participated in the round. This new round, which follows rapid global market expansion after Groundwork BioAg’s $11 million raise in 2021, underscores the demand for biologicals that increase yield while providing carbon mitigation, sequestration, and regenerative solutions. “Building upon our proven science and trusted network of distributors, Groundwork BioAg’s Mycorrhizal BioPlatform, which delivers ROI to both conventional and regenerative farmers while permanently sequestering carbon in their fields, is uniquely positioned to help farmers around the world manage mounting economic and environmental pressures,” said Dr. Yossi Kofman, Co-Founder and CEO of Groundwork BioAg. The company has established commercial operations across the world’s major breadbaskets, including the United States, Brazil, China, India, Canada, Ukraine, and other countries in Europe, Asia and Africa, to improve the efficiency of major crop production, including corn, soybean, grains, fruits and vegetables. “We search for commercial solutions that can deliver the greatest amount of decarbonization in the shortest period of time, and Groundwork BioAg fits that profile squarely,” said Nelson Switzer, Co-Founder and Managing Partner of ClimateIC. “Groundwork BioAg has the technology, team, expertise, and network to help farmers leverage a cost-effective solution to reduce fertilizer use, increase crop yield and restore soil health while mitigating and sequestering an extraordinary measure of carbon.” Based on naturally robust strains of mycorrhizal fungi that are symbiotic with 90% of plant species, Groundwork BioAg ’s Mycorrhizal BioPlatform can easily integrate into local planting regimes and fertility programs. “As demand for nature-based, climate solutions accelerates, investing in businesses with a strong potential climate impact is aligned with HSBC sustainability goals,” said Idan Mor, Investment Director, Climate Technology Ventures for HSBC. “Groundwork BioAg offers a compelling net-zero alternative to a critical area of the global economy – our food supply.” "AgTech is one of our key global investment priorities. Groundwork BioAg's founders have developed a highly effective product for widespread use in agriculture that can substantially reduce fertilizer dependency by making phosphorus available to the plant roots. Furthermore, it has the potential to convert and store CO2,” said Markus Solibieda, Managing Director of BASF Venture Capital GmbH. About Groundwork BioAg Groundwork BioAg, a global bioagriculture company, leverages the natural power of mycorrhizal fungi to improve the productivity, sustainability and profitability of commercial agriculture and expand regenerative agriculture practices. Groundwork BioAg is the first to use innovative techniques to solve challenges inherent in high-volume mycorrhizal inoculant production. We will not rest until every hectare of arable land is protected by mycorrhizae and every farmer benefits from higher crop yields while preserving our soils and permanently sequestering carbon. For more information, visit www.groundworkbioag.com. About Climate Innovation Capital Climate Innovation Capital (ClimateIC) is a growth fund investing in technology and service businesses focused on climate change. We find, fund and grow climate innovations with the highest projected financial returns and the greatest decarbonization potential – delivered in the shortest period of time. We leverage our strong network and our extensive experience as operators, climate advisors and investment professionals to source attractive opportunities and enhance the growth prospects of our investments. Visit https://climateic.com/ Contact Details AgTech PR for Groundwork BioAg Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

August 18, 2022 08:00 AM Eastern Daylight Time

Urban Health creates world’s smartest wellness assistant as it secures $3.4m funding round

Urban Health

Digital wellness company Urban Health which helps people sleep better, relax and de-stress is today announcing a $3.4m seed funding round as they scale operations globally. Having grown quickly in the US with wide acclaim (4.8 star app rating) they will launch a more personalized service for users. The funding round was led by 3one4 Capital with participation from Venture Highway, Founder Bank Capital and Disney’s Ajay Arora. The Urban Health app smart wellness assistant tracks sleep, steps and mindful minutes while using psychology, personal text-based health coaching and premium recorded audio sessions, to create personalized wellness plans for users to de-stress, relax, improve sleep quality and overall well-being. Meditation and sleep sessions offer guided mindfulness, daily motivation, guided sleep meditations and coaching by world-renowned experts, personalized for the way users live their life. In 2020, Urban raised a $400K pre-seed led by Venture Highway, taking their total funds raised to $3.8M. Co-founders Kshitij Jaggi, Rishabh Sahu and Shivang were IIT Kanpur class fellows and established Urban in 2018 upon graduating. Kshitij was a keen user of fitness and wellness apps on his way to losing 20 kgs and Rishabh had been meditating since his teenage years. While Shivang was already coding tech for consumer products in less than a day, at record speeds. Their personal experiences led them to the problem of plenty: screen time, stress, information overdose, sugar, food, weight gain. The pandemic and customer feedback made them focus on stress, sleep and insomnia use cases and landed on wellness as a broader addressable market because it linked all the problems to each other. Urban operates in an estimated $1.5 Trillion wellness market. Addressing burning consumer wellness issues of anxiety, sleep and lack of mental health infrastructure. National Institutes of Health says nearly 1 in 3 of all adolescents ages 13 to 18 will experience an anxiety disorder. Nearly half of the world’s population does not get enough sleep. In addition to the detrimental effect on health, sleep deprivation carries high economic costs, estimated at $680 billion a year in five OECD countries including $400 billion for the United States and $60 billion for Germany. Moreover, to better understand US mental health infrastructure: 40% of the US population live in a limited access area to such services and 60% of US counties have no psychiatrist. Demand outstrips supply by 25 times. Kshitij Jaggi, co-founder at Urban commented: “We made a deep dive into this space and realized every customer's journey is different and everyone needs different kinds of assistance. This is at the heart of what we’ve built until now and where we will continue to innovate. Addressing different customer wellness needs and assisting members based on goals is key to what we do. We assist with deep insights, nudging our members to take the right actions at the right time.” Urban Health analyzed user outcomes over a 4-week usage period and found 85% reported improvement in over well-being. Outcomes included better sleep, less stress and more relaxed state of mind in members. The company plans to further invest in efficacy and support clinical studies in this direction. “Just five minutes of mindfulness and meditation per day can improve your life through stress relief and improved sleep. By helping users stay calm and relaxed, it has increased self-awareness and their sense of perspective. Urban Health brings wellness to your pocket and on the go” added Kshitij Jaggi. Company became revenue generating in January 2021 having launched an annual membership service. Demand surged in the US and revenues have grown 20x since then. Urban will use the funds raised to scale its member base and to provide one-to-one professional help via audio and video calls from health coaches. In addition to this, the company plans to provide health and wellness plans for larger communities through partnerships with schools and companies globally. Anurag Ramdasan, Partner at 3one4 capital commented: “Urban health's adoption has taken off. Downloads are up and consumer spend is taking off. We're seeing a sentiment shift: globally people are prioritising their health and are open to invest in their personal wellness needs. Urban health has successfully scaled their reach globally and we are delighted to support the next phase of growth.” Neeraj Arora, Founding Partner at Venture Highway commented: “Proud to be associated with the team since day zero, true product builders at heart. We’re committed to solving the most urgent global health problem of our times with Urban Health.” About Urban Health Urban Health is the world's smartest wellness assistant. Members globally use it to stress less, relax more and sleep better. Platform offers personalized wellness plans for mind, body and sleep. It uses wellness tacking, psychology, personal text based health coaching and premium recorded sessions to help people lead a healthy life.For more information please visit https://urban.health/ Contact Details Urban Health Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://urban.health/

August 17, 2022 11:43 AM Eastern Daylight Time

Image

Fullintel Appoints Angela Dwyer as Head of Insights

Fullintel, LLC

Fullintel, a leading media monitoring and media intelligence service, is proud to announce it has appointed Angela Dwyer, a leader in the global PR measurement industry, as its new Head of Insights. A former senior vice-president at NYC-based PR agency Lippe Taylor and senior project manager at PRIME Research (now Cision), Angela has spent years developing and implementing advanced media metrics – such as the Hypatia Gravity Score – to help improve the effectiveness of PR campaigns and media outreach. She’s also actively involved in the Institute for Public Relations (IPR) and International Public Relations Research Conference (IPRRC). Building on Fullintel’s Award-Winning Media Measurement Foundation “Fullintel has mastered a cost-effective, human-curated media monitoring approach,” explains Dwyer, “along with a great analysis foundation in terms of Fullintel’s Media Impact Score and PredictiveAI™ crisis module. I want to continue adding to that by customizing the approach for each client based on a range of factors, such as drivers of recall, predictors of how someone might think about your brand, or even different audience drivers depending on the client’s goal.” Angela’s addition builds on Fullintel’s growing momentum in the PR measurement industry, culminating in the company winning Gold, Silver, and Bronze awards at the 2021 AMEC Awards for media measurement. “Angela is one of the most talented senior members of the global measurement community, period. We’re extremely proud to have her join our team,” said Fullintel President Andrew Koeck. “We look forward to providing our clients across healthcare, tourism, retail, aviation, and other industries with even more impactful and actionable insights, based on our ever-evolving measurement program and new products such as PredictiveAI.” Improving Measurement Standards For Communicators Angela is a regular on several industry committees and boards, including the International Public Relations Measurement Commission. She’s also set to join other media measurement experts in hosting the Institute of Public Relations (IPR) Master Class, a strategic playbook for communicators featuring eight live and interactive sessions from Sept. 19, 2022 to April 18, 2023. About Fullintel: Fullintel combines best-in-class technology with expert content curation to deliver the most relevant, cost optimized media monitoring, daily news briefs, and media analysis possible. Our analysts curate print, online, social media, broadcast, and influencer opinions in real time compiled by technology, supplemented and verified by humans. Where technology alone fails, your dedicated analyst has you covered. Fullintel has offices in Cambridge, Mass., Ottawa, Ont. and Nagercoil, India. Contact Details Fullintel Samuel Chen +1 339-970-8005 schen@fullintel.com Company Website https://fullintel.com/

August 17, 2022 10:20 AM Eastern Daylight Time

Video Image

Pinnacle Financial Services Partners with Health One to Expand Market & Agent Opportunities

AmeriLife

Pinnacle Financial Services, one of the largest, full-service health, life, annuities and long-term care national marketing organizations and an affiliate of AmeriLife Group, LLC (“AmeriLife”), announced today that it has acquired Health One Corporation (“Health One”). A Miami-based insurance marketing organization, Health One specializes in the distribution of Medicare Advantage, Medicare Supplement and Affordable Care Act (ACA) health insurance products for beneficiaries in the under-65 U.S. Hispanic market. Per the agreement, terms of the deal were not disclosed. “Our world is changing every day,” said Pinnacle Financial Services CEO Kevin Shields. “A single message does not work anymore. Therefore, we pride ourselves on recognizing and developing partnerships with brands like Health One.” Founded in 2016 by Susan Carrasco, Health One has carved out a significant place in the Medicare and ACA health insurance arena as one of the few true multicultural and multilingual insurance marketing organizations in the United States. Health One supports over 400 licensed agents in more than 30 states, who offer their services in Portuguese, Creole and French in addition to English and Spanish. With the increased capital, resources and support from Pinnacle, Health One will be well positioned to accelerate its growth, expand its agent base and serve more clients nationwide. “At Health One, we work to recognize and embrace the many diverse markets in both the ACA and Medicare arena,” said Health One Founder and CEO Susan Carrasco. “By recognizing our partners’ different cultures, communities and unique needs, we connect authentically while creating an experience that is inclusive to all. As a leading provider of agent training and support, we then help our distribution use those skills – and tailor the right products – to meet our client’s needs.” “The fast-growing U.S. Hispanic market has been a strategic priority for our distribution efforts for many years, and today’s announcement with Pinnacle is another example of our combined commitment to meet the needs of an increasingly diverse pre-retiree and retiree population,” added AmeriLife Chief Distribution Officer Mike Vietri. “I’m thrilled to welcome Susan and the Health One team into the AmeriLife family of companies under Kevin’s leadership, and we look forward to helping them achieve continued scale, growth and success together.” Health One will continue to operate as a stand-alone organization, headquartered in Miami and led by Carrasco, who will report to Pinnacle Financial Services’ Chief Operating Officer, Angela Palo. ### About Pinnacle Financial Services Pinnacle Financial Services is a national marketing organization licensed in all 50 states. The company is dedicated to serving independent insurance agents and agencies by providing world-class service, training and back-office support. Visit PFSInsurance.com and follow Pinnacle Financial Services on Facebook and LinkedIn for more information. About Health One Corporation Health One Corporation is a leading provider of training for both the Affordable Care Act (ACA) and Medicare markets. Our mission is to deliver excellent health care solutions to both individuals and families nationwide. For more information, visit HealthOneCorp.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Inquiries Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Pinnacle Financial Services - Partnership Inquiries Bob Brzyski +1 800-772-6881 bbrzyski@pfsinsurance.com AmeriLife - Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com

August 17, 2022 09:00 AM Eastern Daylight Time

Is BioLife Sciences (OTCPK: BLFE) An OTC Company Primed For Growth?

BioLife Sciences Inc

BioLife Sciences Inc. (BioLife), a commercialization accelerator, licensor and developer of technologies, has reportedly provided investors with a significant company update throughout the course of a two-year transformation. Over the course of the last two years, BioLife has gone through a number of changes evolving into a revamped corporate entity focused on disrupting various consumer verticals, with a specific focus on health and wellness. Let’s take a look at some of what the company has been up to over the last two years. BioLife Sciences is Born: In June of 2020, the OTC Markets public entity formerly known as Rhino Novi Inc. (RNOV) underwent a reverse merger transaction – changing its name and ticker symbol to BioLife Sciences Inc. (BLFE). While Rhino Novi originally focused on VOIP products, the newly formed BioLife would focus on developing and marketing disruptive technologies to a variety of consumer verticals. Harnessing the Antimicrobial Power of Copper? BioLife has reported it focused on the utilization of the natural antimicrobial power of copper and harnessing its innate benefits into everyday textiles. This dynamic elemental metal has a wide variety of beneficial traits, including being required by all plants and animals as a key mineral and nutrient necessary for survival. In the case of humans specifically, copper reportedly helps to boost red blood cell production, provides support to the immune system, and helps to keep nerve cells healthy. For plants, copper is a fundamental micronutrient that is a critical element of plant enzymes, it is essential for plants’ respiration, plays a key role in plant cell wall strength and contributes to the overall strength of the plant. More recently, copper has been shown to provide antimicrobial efficacy associated with copper alloy touch surfaces. Some hospital studies have shown copper’s effectiveness in lowering E.coli counts on brass doorknobs, as well as SARS-CoV-2, Rhinovirus Type 37, Rotavirus Strain WA, and Human Coronavirus 229E. BioLife says it has focused its attention on incorporating the power of copper into everyday products which are fabric-based and disruptive, in contrast to the market’s current offering. Some of these products in development include copper-infused fabric gardening pots, copper-infused gardening gloves, copper-infused microfiber towels and copper-infused air filters. What is MFusion? The company states that traditional copper-infused products that consumers will find on the market today provide limited-to-partial copper coverage. This means that there could are often gaps in the copper coverage, resulting in less-than-optimal results. BioLife addresses this problem with the introduction of their unique copper infusion process: MFusion. MFusion infuses copper into every sub-bundle of the fabric, providing more complete coverage. When copper is infused into textiles via MFusion, the resulting fabrics benefit from 100% evenly distributed copper coverage. MFusion can be applied to any textile – from t-shirts to air filters – with the result being total copper infusion. The 2022 Acquisition of Health Box LLC – What’s Next? In February of 2022, BioLife completed the acquisition of Health Box LLC – an Arizona-based orthomolecular medicine and natural health products company. By completing this acquisition - and appointing Nika Jaksic, Health Box’s founder, as the new COO, the company believes it has positioned itself to enter the orthomolecular and natural health products space. In order to facilitate the Company’s aggressive expansion plans, the Company filed for a Regulation A+ Tier 1 Offering. The SEC qualified BioLife and the Company is eligible to raise up to $20 million. If successful in its capital raise, BioLife states that they intend to pursue rapid expansion of its existing and contemplated product offerings, audits, and the potential of filling towards uplisting to the OTC Venture Market (OTCQB). This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. BioLife Sciences Inc. specializes in moving innovative products from the lab or small-scale production into wider market adoption. Its core business develops, licenses and distributes antimicrobial products and disruptive technology. One of BioLife Sciences’ core building block strategies is to develop, partner and assist innovative companies with the commercialization of leading-edge technologies. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Contact Details BioLife Sciences ir@biolifesciences.com Company Website https://www.biolifesciences.com

August 16, 2022 01:25 PM Eastern Daylight Time

NextFerm Technologies announces a $3 million Supply agreement for its vegan protein: ProteVin™

NextFerm Technologies Ltd.

A 4.5 years supply agreement with Spacemilk, an American health and sports nutrition brand Currently, the company has a base of potential customers, including global food, dietary supplement companies and international brands, who are examining the integration of ProteVin™ in a variety of alternative products (Yokneam Illit, August 8, 2022) – NextFerm Technologies Ltd. (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, fermentation-based, non-GMO protein alternative and other innovative yeast-based nutrients, announced today that it has entered into a 4.5 years supply agreement totaling approximately $3 million with Spacemilk., an American vegan health and sports nutrition brand. This agreement includes the initial supply of protein in the amount of few tons carried out in June 2022. As reported to the company, Spacemilk is expected to launch in the fourth quarter of 2022 and for the first time in the U.S., a vegan sports nutrition protein powder based on ProteVin™. The agreement stipulates that Spacemilk will promote the ProteVin™ brand on the product packaging, as it is the dominant nutritional component underlying the product. The agreement includes a mutual commitment to purchase and supply ProteVin™ totaling approximately $1.6 million from July 2022 until the end of June 2025, and an estimation of an additional purchases of $1.4 million by the end of 2026. It should be noted that until the expected operation of the expanded production facility in 2023, the Company will supply protein in the amount of few tons.The company is making progress in its strategic plan and in achieving the other goals it set for itself for 2022, including: Generating demands and receiving additional purchase orders. The company presents the product at exhibitions of raw materials for food and dietary supplements in the US, Europe and Asia and accelerates launching efforts. Currently, the company has a base of potential customers, including global food, dietary supplement companies that are in various stages of evaluating ProteVin™ and integrating it into a variety of vegan products. Expanding ProteVin's production capacity from an initial capacity of tens of tons per year, to a scale of hundreds of tons per year in 2023 which expected to begin during the second half of 2022. Boaz Noy, Chief Executive Officer of NextFerm, said: "We are pleased to announce the first multi-year supply agreement for ProteVin™. This is an important step towards realizing the company's vision of positioning ProteVin™ as a leading vegan protein in the thriving global alternative protein industry. ProteVin™ is gaining a lot of interest from global food and dietary supplement companies and is currently being tested by dozens of potential customers. This customer base continues to grow and is expected to yield the company the following agreements. At the same time, we are preparing to increase production capacity to a scale of hundreds of tons in 2023, to meet the demand." Walter Ross, Chief Executive Officer and Founder of Spacemilk, said: "Based on my background and experience in sports nutrition - as a business owner, personal trainer, and consumer in the industry, I can say that ProteVin™ is everyone’s perfect protein. ProteVin’s unique qualities provide amino acid content like whey, ethics and sustainability superior to plant proteins, and a flavor profile that’s better than both. My company, Spacemilk, only sources the highest quality, cleanest, and most sustainable and effective ingredients, which made developing our flagship product with ProteVin™ an easy choice. We’re excited to take ProteVin™ and be first to market with a new category of protein powder, which we believe will replace large sections of the plant and animal nutrition industry today." About NextFerm Technologies NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE:NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives. NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein with animal-like nutritional value (Amino acid profile BCAA=21%, Leucine=9%, EAA=53% and high digestibility PDCAAS=1) and a neutral flavor. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at USD 20 billion in terms of final products and at USD 3.5 billion in terms of raw materials with an annual growth rate of above 20%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. Another product currently being sold is Astaferm®, an innovative astaxanthin-based antioxidant derived from yeast that has been sold in the US since the end of 2020 through well-established and leading brands in the food supplement market in the US. In July 2021, the Company received Regulatory marketing approval in Canada. The company has additional products which have been licensed to Lallemand, a global giant focused on yeast. For more information, visit the NextFerm website at: www.nextferm.com Legal Notice Regarding Forward-Looking Statements This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company’s control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company’s operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company’s current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company’s operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors. Contact Details Investor and Media Contact Meirav Gomeh-Bauer +972 54-476-4979 meirav@bauerg.com Company Website https://www.nextferm.com/

August 16, 2022 11:09 AM Eastern Daylight Time

Code 1 Supply Named as Exclusive Distributor for XDcuff® Patient Restraint System

Code 1 Supply

Code 1 Supply, the leading distributor of best-in-class medical diagnostics and brand-name supplies, has been named as the exclusive distributor of XDcuff®, a stretcher-integrated limb restraint system for emergency medical service providers. XDcuff is a patented clip-in or secure-in reusable limb restraint system that greatly reduces the risk of patient injury by decreasing the amount of time EMS providers spend with uncooperative patients. The system allows medics to quickly anchor limb restraints, without confusion or special knots to be formed. The product has been perfected after several years of development and made by the people who use them – paramedics. “We are honored to partner with XDcuff exclusively to offer their innovative patient restraint system to new and existing Code 1 Supply clients,” said Matt Regan, CEO at Code 1 Supply. “I have experienced firsthand the need for a more robust patient restraint system that allows paramedics to quickly and easily restrain a patient that is a risk to themselves or to others during transit. XDcuff provides the security that EMS providers are looking for, and I look forward to working directly with EMS teams nationwide to offer XDcuff on their ambulances.” Working in collaboration, Code 1 Supply and XDcuff will be attending EMS-focused events in the coming months in order to demonstrate the ease of use and importance of the XDcuff patient restraint system for EMS teams. Team members from both companies will be at EMS World Expo October 12-14 in Orlando, FL (Booth #1204) and at EMS Pro Expo & Conference at Foxwoods Casino in Connecticut October 26-29 (booth #528), where attendees can learn more about XDcuff and other product offerings from Code 1 Supply. “Our team at XDcuff looks forward to working exclusively with Code 1 Supply to bring our patient restraint system to EMS teams nationwide,” said David Dufek, CEO at XDcuff. “As a paramedic myself, I know the importance of safe patient transport for both patient and EMS provider. Working with Code 1 Supply, another paramedic-owned company, I know we will be able to make a great impact on efficiencies within the ambulance while ensuring safe transport of confused or agitated patients.” Representing the most trusted and respected manufacturers of medical diagnostics, supplies and equipment, Code 1 Supply offers next-day shipping for all orders and free shipping on orders over $750. The XDcuff patient restraint system is now available exclusively through Code 1 Supply. To learn more about how the company can support your patient restraint needs, please visit https://www.code1supply.com/. About Code 1 Supply Code 1 Supply is an international distributor of best-in-class medical diagnostics, brand-name supplies, and equipment, and a leading provider of CPR training equipment and student materials. Representing the most trusted and respected manufacturers of medical diagnostics, supplies and equipment, Code 1 Supply is committed to providing innovative products and outstanding services at the best prices. We are proud to be the medical supply partner for healthcare providers, hospitals, urgent care centers, businesses and communities worldwide. For more information, visit www.code1supply.com. About XDcuff® XDcuff® Clip-In or Secure-In Reusable Limb Restraints greatly reduce the risk of injury by simply reducing the amount of time EMS providers spend with uncooperative patients. Improve treatment and on-scene times when treating confused and agitated patients. Using a standard application plan helps eliminate any confusion on how or where to anchor restraints. Improve safety without the high cost. We developed XDcuff out of necessity and offer our system at a competitive price. Our innovative design change pre-connects the anchors (clips) to the stretcher for fast access and deployment in these emergencies. No more time wasted searching, looping, or tying special quick release knots. Eliminating these steps has proven to greatly reduce restraint times providing for a much safer and more effective work environment. Visit https://www.xdcuff.com/ for more information. Contact Details Rita Murphy +1 774-454-1516 rita.murphy@svmpr.com Company Website https://www.code1supply.com/

August 16, 2022 10:00 AM Eastern Daylight Time

Don’t Give This Company The Brush Off? Brüush Offers Mid-Priced Electric Toothbrush In An Interesting Market

Bruush Oral Care Inc.

While the jury’s still out on whether electric toothbrushes are more effective than manual ones, a number of companies are betting consumers will increasingly adopt them. https://profiles.smallcapsdaily.com/bruush/ The American Dental Association says both manual and electric brushes remove plaque and bacteria from teeth — so long as you’re using a proper brushing technique. More recently, the Journal of the American Dental Association published a survey that found that 13,000 out of 16,000 patients who used an electric toothbrush reported better oral health. The global electric toothbrush market size was estimated to be worth $4.3 billion in 2022 and projected to increase to just over $6 billion by 2027, according to Statista. Some are betting big with high-priced devices, while others are banking on consumers looking for value. And then there are those that fall somewhere in the middle. Koninklijke Philips N.V.’ s (NYSE: PHG) Sonicare line has a variety of options, with the least expensive starting at about $20 and the company’s most advanced electric toothbrush — which gets guidance from an app using artificial intelligence — selling for $380. Joining Philips with a lower-end offering is Quip. Starter kits for Quip’s adult electric toothbrushes start at $20. You get the handle with three-month battery life, a soft-bristle brush head and a cover. Quip will send you a new brush head and free battery every three months for $5. Brushing Off The Competition? Then there’s Brüush (NASDAQ: BRSH), which says it takes the confusion out of deciding what to buy with its $79 electric toothbrush kit. Brüush, which comes in three core colors and the seasonal colors, has six cleaning modes for every type of brusher. The company’s website says Gentle makes smiles clean and bright, while the Tongue mode keeps your mouth smelling fresh. Brüush estimates 70% of its customer base is between ages 18 and 45 years old, a group that’s under-penetrated compared to baby boomers in terms of using an electric toothbrush. This age group also consists of the first digital generations when it comes to shopping and e-commerce brand loyalty to businesses like Apple Inc. (AAPL), perhaps a positive for a company where the website accounts for the majority of sales. If you’re in the market for an electric toothbrush, Brüush says to be sure to buy one that comfortably fits inside your mouth — usually, smaller is better so you can maneuver it to make sure you’re brushing all your teeth. Looking for a brush with soft bristles that are gentle on teeth and gums to avoid irritation is a good idea — a self-timer feature also is recommended to ensure you brush the full two minutes dentists recommend. Toothbrush heads should be replaced every 12 weeks — which makes Brüush’s subscription model that sends customers three new brush heads for $18 every six months a convenient way to stay on top of changing them. By comparison, replacing brush heads for Sonicare products can cost as much as $43 for a three-pack, and the price of the Procter & Gamble Co. (NYSE: PG) Oral-B line of replacement brush heads reaches as high as $40 for a three-pack. Visit Brüush’s website to learn more about the company and its products. About Bruush Oral Care Inc. Bruush Oral Care Inc. is on a mission to inspire confidence through brighter smiles and better oral health. Founded in 2018, Brüush is an oral care company that is disrupting the space by reducing the barriers between consumers and access to premium oral care products. The Company is an e-commerce business with a product portfolio that currently consists of a sonic-powered electric toothbrush kit and brush head refills. Brüush has developed a product to make upgrading to an electric brush appealing with three core priorities in mind: (i) a high-quality electric toothbrush at a more affordable price than a comparable electric toothbrush from the competition; (ii) a sleek, countertop-friendly design; and (iii) a convenient brush head refill subscription program that eliminates the frustrating experience of purchasing replacement brush heads at the grocery/drug store. The Company is rooted in building a brand that creates relevant experiences and content, with the goal of becoming the go-to oral care brand for millennials and Generation Z.For more information on Bruush Oral Care Inc visit https://bruush.com. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR - Colette Eymontt colette@tradigitalir.com Company Website http://www.tradigitalir.com

August 16, 2022 08:56 AM Eastern Daylight Time

1 ... 204 205 206 207 208 ... 300